AORT

CryoLife, Inc. (ARTIVION) Q2 2010 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2010 for CryoLife, Inc. (Note: The input metadata lists "ARTIVION, INC." but the filing text explicitly identifies the registrant as CryoLife, Inc.). CryoLife preserves and distributes human tissues (cardiac and vascular) and develops medical devices including surgical adhesives (BioGlue, BioFoam) and hemostats (HemoStase). The company operates two reportable segments: Preservation Services and Medical Devices.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 4% for the quarter and 8% for the six-month period compared to 2009. Preservation services revenue grew 6% (quarter) and 11% (six months), driven by higher cardiac and vascular tissue shipments. Product revenue grew 2% (quarter) and 5% (six months), primarily due to a 29% increase in HemoStase sales.
• Cost Pressures: Cost of preservation services increased 12% (quarter) and 19% (six months), outpacing revenue growth due to higher per-unit processing costs and decreased throughput. Gross margin percentages remained relatively stable but faced pressure from these cost increases.
• Non-Operating Items: The company recorded a non-cash gain of $385,000 (quarter) and $1.2 million (six months) on the valuation of a derivative liability related to its investment in Medafor, Inc. This gain significantly boosted net income.
• Operating Expenses: General, administrative, and marketing expenses decreased 5% for the quarter but increased 2% for the six months, largely due to legal fees associated with litigation against Medafor and patent litigation in Germany.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• HemoStase: Management expects HemoStase revenues to increase for the full year 2010, projecting $6.0 to $7.0 million in future sales based on current inventory, provided the distribution agreement remains intact.
• CryoValve SGPV: The company received FDA clearance for a five-year shelf-life on its CryoValve SGPV, which is expected to improve tissue mix and revenue in the remainder of 2010.
• Stock Repurchase: The Board authorized a $15.0 million stock repurchase program. As of June 30, 2010, $1.5 million had been utilized.

• Medafor Litigation (Critical): CryoLife is engaged in ongoing litigation with Medafor, Inc., the manufacturer of HemoStase. Medafor has issued multiple notices of termination regarding the Exclusive Distribution Agreement (EDA). On July 27, 2010, Medafor notified CryoLife of an intent to terminate the EDA effective August 27, 2010, alleging material breach. If the EDA is terminated, CryoLife will be unable to distribute HemoStase, which would materially adversely impact revenues.
• Medafor Investment: CryoLife holds approximately 2.4 million shares of Medafor common stock (carrying value $6.2 million). The company faces risks of impairment if the value of this investment declines or if the relationship with Medafor deteriorates further.
• German Patent Litigation: A German court declared CryoLife's main BioGlue patent void. CryoLife has appealed; if the appeal fails, the company may be unable to enforce patent rights in Germany, though it can continue sales.
• Liability Claims: The company has accrued $3.0 million for unreported tissue processing and product liability claims, with a potential exposure as high as $5.2 million based on higher frequency estimates.

Investor Verification Checklist

• EDA Status: Verify the current status of the preliminary injunction motion and the July 27, 2010 termination notice from Medafor. Determine if the EDA remains in force.
• HemoStase Supply Chain: Confirm if Medafor is fulfilling purchase orders and if inventory levels are sufficient to meet the projected $6.0–$7.0 million in sales.
• Medafor Investment Valuation: Assess the likelihood of an impairment charge on the $6.2 million Medafor equity investment given the strained relationship and litigation.
• German Patent Appeal: Monitor the timeline and potential outcome of the appeal regarding the BioGlue patent nullity in Germany.
• Deferred Preservation Costs: Review the trend of deferred preservation costs, which decreased by $2.8 million in the first half of 2010, to ensure this cash flow benefit is sustainable.